Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. FE [Internet]. 2017 Oct. 5 [cited 2025 Oct. 29];18(1). Available from: https://journals.seedstm.com/index.php/FE/article/view/1332